# Featured News

## Exclusive: Biotech’s Latest Unicorn Uses AI to Mine Nature’s Medicine Chest

Nature is a prolific pharmacist. Aspirin, the blood thinner warfarin and metformin for diabetes all trace back to plants, discovered by serendipity before being transformed into drugs by modern chemistry.

[Read More](https://www.bloomberg.com/news/articles/2025-09-04/biotech-s-latest-unicorn-uses-ai-to-mine-nature-s-medicine-chest)

## Enveda named one of the Most Innovative Companies in biotech by Fast Company

[Read More](https://www.fastcompany.com/91497087/biotech-most-innovative-companies-2026)

## Enveda Raises $150 Million To Use AI To Develop Drugs From Nature

[Read More](https://www.forbes.com/sites/innovationrx/2025/09/10/ai-tools-are-spreading-medical-scams-online/)

## Enveda Gets New Backing to Scour Nature for Promising Compounds

[Read More](https://createsend.com/t/d-309EEB88C1495B512540EF23F30FEDED)

## Enveda CEO Reveals How It Will Deploy $150M in Series D Funding

[Read More](https://tv.nyse.com/videos/enveda-ceo-reveals-how-it-will-deploy-150m-in-series-d-funding)

## Enveda raises $150M for drug development, reaching unicorn status

[Read More](https://www.axios.com/pro/biotech-deals/2025/09/04/enveda-raises-150m-unicorn-status)

## Enveda collects another $150M for I&I drug, sprawling pipeline of preclinical assets

[Read More](https://endpoints.news/enveda-collects-another-150m-for-ii-drug-sprawling-pipeline-of-preclinical-assets/)

## Enveda: Cracking the chemical code of life with AI

[Read More](https://enveda.com/news/)

## America’s Greatest Startup Workplaces 2025

[Read More](https://www.newsweek.com/rankings/americas-greatest-startup-workplaces-2025)

## 2025 America’s Best Startup Employers

[Read More](https://www.forbes.com/lists/americas-best-startup-employers/)

## AI Drug Discovery Startup Enveda Raises $130 Million

[Read More](https://www.bloomberg.com/news/articles/2024-11-21/ai-drug-discovery-startup-enveda-raises-130-million?srnd=undefined)

## Enveda raises $55M to combine ancient remedies with AI for drug discovery

[Read More](https://techcrunch.com/2024/06/14/enveda-raises-55m-to-combine-ancient-remedies-with-ai-for-drug-discovery/)

## Enveda translates life’s chemistry into medicines

[Read More](https://www.reuters.com/plus/acumen/global-health/enveda-lifes-chemistry-biodiversity)

## TRANSFORMing natural product drug discovery: machine learning for high-fidelity chemical property prediction from metabolomics data

[Read More](https://www.biospace.com/enveda-s-matured-platform-drives-toward-three-inds-in-2023)

## Press Releases

### Enveda Appoints Christopher K. Porter, MBA, JD as Senior Vice President, Clinical Operations

[Read More](https://www.businesswire.com/news/home/20260415472560/en/Enveda-Appoints-Christopher-K.-Porter-MBA-JD-as-Senior-Vice-President-Clinical-Operations)

### Enveda Reports Positive Results for ENV-294 in a Phase 1b Clinical Trial of Patients with Moderate-to-Severe Atopic Dermatitis

[Read More](https://www.businesswire.com/news/home/20260331510616/en/Enveda-Reports-Positive-Results-for-ENV-294-in-a-Phase-1b-Clinical-Trial-of-Patients-with-Moderate-to-Severe-Atopic-Dermatitis)

### Enveda Advances Third Asset to the Clinic With US FDA IND Clearance and Phase 1 Initiation of ENV-6946, a First-in-Class Oral “Multi-Biologic in a Pill” for Inflammatory Bowel Disease

[Read More](https://www.businesswire.com/news/home/20251223284016/en/Enveda-Advances-Third-Asset-to-the-Clinic-With-US-FDA-IND-Clearance-and-Phase-1-Initiation-of-ENV-6946-a-First-in-Class-Oral-Multi-Biologic-in-a-Pill-for-Inflammatory-Bowel-Disease)

### Enveda Announces US FDA IND Clearance and First Patient Dosed in Phase 1 Trial of ENV-308, a First-in-Class Oral Therapy for Obesity

[Read More](https://www.businesswire.com/news/home/20251217651699/en/Enveda-Announces-US-FDA-IND-Clearance-and-First-Patient-Dosed-in-Phase-1-Trial-of-ENV-308-a-First-in-Class-Oral-Therapy-for-Obesity-Appoints-Nadeem-Sarwar-Ph.D.-MPharm-MPhil-to-Lead-Metabolic-Disease-Strategy)

### Enveda Initiates Phase 2 Clinical Trials of ENV-294, a First-in-Class Oral Therapy in Atopic Dermatitis and Asthma

[Read More](https://www.businesswire.com/news/home/20251209287981/en/Enveda-Initiates-Phase-2-Clinical-Trials-of-ENV-294-a-First-in-Class-Oral-Therapy-in-Atopic-Dermatitis-and-Asthma)

### Enveda Reports Favorable Phase 1 Safety for Novel Oral Anti-Inflammatory, Launches Phase 1b Trial in Atopic Dermatitis

[Read More](https://www.businesswire.com/news/home/20250528125414/en/Enveda-Reports-Favorable-Phase-1-Safety-for-Novel-Oral-Anti-Inflammatory-Launches-Phase-1b-Trial-in-Atopic-Dermatitis)

### Enveda Gains Backing from Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing Total Series C Financing to $150M

[Read More](https://www.businesswire.com/news/home/20250226020142/en/Enveda-Gains-Backing-from-Sanofi-to-Advance-AI-Driven-Drug-Discovery-to-Clinical-Trials-Bringing-Total-Series-C-Financing-to-%24150M)

### Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board

[Read More](https://www.businesswire.com/news/home/20250205061722/en/Enveda-Expands-into-Asthma-with-First-in-Class-Lead-Asset-ENV-294-and-Assembles-World-Class-Advisory-Board)

### Enveda Welcomes Jason Kim as Chief Financial Officer

[Read More](https://www.businesswire.com/news/home/20250110276665/en/Enveda-Welcomes-Jason-Kim-as-Chief-Financial-Officer)

### Enveda Closes $130M Series C Funding to Deliver Multiple Clinical Readouts from a Pipeline of 10 Development Candidates

[Read More](https://www.businesswire.com/news/home/20241121310215/en/Enveda-Closes-130M-Series-C-Funding-to-Deliver-Multiple-Clinical-Readouts-from-a-Pipeline-of-10-Development-Candidates)

### Enveda Announces First Candidate Discovered From Nature Using AI Advances to Clinical Trials

[Read More](https://www.businesswire.com/news/home/20241113334257/en/Enveda-Announces-First-Candidate-Discovered-From-Nature-Using-AI-Advances-to-Clinical-Trials)

### Enveda Biosciences Hires Chief Medical Officer to Advance Its Rich Pipeline of Therapeutic Programs into the Clinic

[Read More](https://www.businesswire.com/news/home/20240801312880/en/Enveda-Biosciences-Hires-Chief-Medical-Officer-to-Advance-Its-Rich-Pipeline-of-Therapeutic-Programs-into-the-Clinic)

### Enveda Raises $150M Series D Funding to Reach Unicorn Status, Enrolls First Patient in Lead Program

[Read More](https://www.businesswire.com/news/home/20250904184822/en/Enveda-Raises-%24150M-Series-D-Funding-to-Reach-Unicorn-Status-Enrolls-First-Patient-in-Lead-Program-and-Adds-Mikael-Dolsten-to-Board-of-Directors)

### Enveda Biosciences Announces $55M in New Funding to Accelerate Platform and Advance Multiple Candidates to Clinical Trials

[Read More](https://www.businesswire.com/news/home/20240614326580/en/Enveda-Biosciences-Announces-%2455M-in-New-Funding-to-Accelerate-Platform-and-Advance-Multiple-Candidates-to-Clinical-Trials)

### Enveda Biosciences Announces Microsoft Collaboration and Reveals Foundation Model to “Read and Translate” Chemistry

[Read More](https://www.businesswire.com/news/home/20240529298878/en/Enveda-Biosciences-Announces-Microsoft-Collaboration-and-Reveals-Foundation-Model-to-%E2%80%9CRead-and-Translate%E2%80%9D-Chemistry)

### Enveda Biosciences unveils new AI algorithm to unlock nature’s chemical code

[Read More](https://www.businesswire.com/news/home/20230621191398/en/Enveda-Biosciences-unveils-new-AI-algorithm-to-unlock-nature%E2%80%99s-chemical-code)

### Enveda Biosciences Announces Oversubscribed Series B1 Bringing Total Round to US$119 Million

[Read More](https://www.businesswire.com/news/home/20230420005405/en/Enveda-Biosciences-Announces-Oversubscribed-Series-B1-Bringing-Total-Round-to-US%24119-Million)

### Enveda Biosciences Closes $68-million Combined Series B Equity and Debt Financing

[Read More](https://www.businesswire.com/news/home/20221221005152/en/Enveda-Biosciences-Closes-%2468-million-Combined-Series-B-Equity-and-Debt-Financing)

### Enveda Biosciences Closes $51M Series A Financing Led by Lux Capital

[Read More](https://www.businesswire.com/news/home/20210622005100/en/Enveda-Biosciences-Closes-%2451M-Series-A-Financing-Led-by-Lux-Capital)